Personalis Inc.
Personalis is a company specializing in advanced genomic testing and liquid biopsy approaches for cancer detection, biomarker discovery, and clinical research. They focus on innovative sequencing technologies and comprehensive tumor profiling to support personalized medicine and cancer research.
Industries
Nr. of Employees
large (251-1000)
Personalis Inc.
Menlo Park, California, United States, North America
Patents
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12270083-B2
View Details
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12270083-B2
View DetailsProducts
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
Services
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Expertise Areas
- Liquid biopsy and circulating tumor DNA analysis
- Tumor genomic profiling and characterization
- Neoantigen discovery and immunogenomics
- NGS assay design and validation
Key Technologies
- Next-generation sequencing (NGS)
- Cell-free DNA (cfDNA) / circulating tumor DNA (ctDNA) analysis
- Targeted oncology gene panels
- Neoantigen prediction algorithms